A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Relatlimab and Nivolumab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma Read more
Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas Read more
A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT) Read more
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Unresected Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867) Read more
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma Read more
Analysis of stem cell products immunological parameters and recipient outcome in autologous and allogeneic peripheral blood stem cell transplantation Read more
Dose Escalation In Patients With Advanced Solid Tumors, And Expansion In Selected Indications Read more
An Open-Label, Multicenter, Dose-Escalation, Phase I Study To Evaluate Safety, Pharmacokinetics, And Preliminary Anti-Tumor Activity Of Ro7444973 In Participants With Advanced And/Or Metastatic Mage A4-Positive, Solid Tumors. Read more
